| Abstrakt: |
Marine algae (seaweeds) have emerged as a promising source in the continuing search for antidiabetic compounds because of their medicinal and nutritional properties. The present study evaluated marine red algae, Portieria hornemannii, for its inhibition of diabetic-linked enzymes (α-amylase, α-glucosidase, and DPP-IV) and antioxidant (DPPH) potential using in vitro assays. Among the tested extracts, ethyl acetate and acetone extract exhibited notable inhibition against α-amylase (IC50: 95.30 μg/mL), α-glucosidase (IC50: 632.5 μg/mL), and DPP-IV (IC50: 36.91 μg/mL). However, the antioxidant activity of the extracts was mild to moderate (17%). Furthermore, the half maximal inhibitory concentration (IC50) of the extracts was found to be non-toxic against mouse macrophage cells (J774) and human red blood cells. Chemical profiling by GC-MS analysis revealed the presence of major bioactive compounds such as phytol, z,z-6,28-heptatriactontadien-2-one, hentriacontane, and l-ascorbic acid. Overall, our findings indicate that the extracts of P. hornemannii reduce postprandial hyperglycemia by inhibiting the release of simple sugars through the inhibition of the enzymes (α-amylase, α-glucosidase, and DPP-IV). [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink